Assertio (ASRT) closed the last trading session at $11.13, gaining 4.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $38.94 indicates a 249.9% upside potential.The average comprises five short-term price targets ranging from a low of $24.74 to a high of $45.00, with a standard deviation of $9.04. While the lowest estimate indicates an increase of 122.3% from the current price le ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Assertio (ASRT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Assertio is a member of our Medical group, which includes 932 different companies and cur ...

LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. ("Assertio†or the "Company†) (NASDAQ: ASRT) today announced that it has received confirmation from The Nasdaq Stock Market LLC ("Nasdaq†) that the Company has regained compliance with all applicable listing requirements. As of January 12, 2026, Nasdaq has determined that Assertio has regained compliance with the Minimum Bid Price Rule, which requires the Company's common stock maintains a minimum bid price of $1.00 per share for a min. ...

"Company†) (Nasdaq: ASRT) today announced that results of a clinical trial investigating a novel dosing schedule of Rolvedon® (eflapegrastim-xnst) injection have been peer reviewed and published in The Oncologist. In the study of patients with early-stage breast cancer (ESBC), Rolvedon, when administered on the same day (same-day dosing) as TC chemotherapy (Taxotere (docetaxel) and cyclophosphamide) demonstrated an e. LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. ("Assertio†or the ...

LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. ("Assertio†or the "Company†) (NASDAQ: ASRT) today announced that it filed a certificate of amendment to its certificate of incorporation (the "Certificate of Amendment†) on December 19 to implement a one-for- fifteen reverse split of its issued and outstanding common stock (the "Reverse Split†). The Reverse Split will become effective as of 12:01 a.m. Eastern Time on December 26, 2025, and the Company's common stock will begin trading. ...

Summary of Key Points Core Insights - Several healthcare and biotech stocks experienced significant gains in after-hours trading following earnings updates and guidance revisions Company Performance - **KalVista Pharmaceuticals Inc. (KALV)**: Stock rose 11.29% to $12.12 after reporting a third-quarter net loss of $49.5 million ($0.92 per share), compared to a loss of $39.1 million ($0.84 per share) in the same period last year. Net product revenue for the quarter was $13.7 million [1] - **Health Catalyst Inc. (HCAT)**: Stock advanced 13.24% to $3.23 after reporting a third-quarter net loss of $22.2 million ($0.32 per share), compared to a loss of $14.7 million ($0.24 per share) a year ago. Revenue declined to $76.3 million from $86.4 million. For Q4 2025, projected revenue is about $73.5 million with adjusted EBITDA of $13.4 million. Full-year expectations are $310 million in revenue and $41 million in adjusted EBITDA [2] - **Bio-Techne Corp. (TECH)**: Stock climbed 8.72% to $62.47. The company reported first-quarter GAAP EPS of $0.24, up from $0.21 last year, while adjusted EPS remained flat at $0.42. Revenue declined 1% year-over-year to $286.6 million [3] - **Assertio Holdings Inc. (ASRT)**: Stock gained 8.30% to $0.87 after reporting third-quarter GAAP net income of $11.4 million ($0.11 per share), compared to a loss of $2.9 million ($0.03 per share) last year. Adjusted EPS rose to $0.18 from $0.02. Net product sales reached $49.5 million, up from $28.7 million [4] - **Abeona Therapeutics Inc. (ABEO)**: Stock moved up 8.51% to $4.59. The company is scheduled to report third-quarter results on November 12, with analysts expecting a loss of $0.34 per share on revenue of $5.53 million [5]

Core Insights - HEXPOL is focusing on strategic direction, operational performance, and new financial targets during the Capital Markets Day in 2025 [1] - The agenda includes presentations on growth, M&A strategy, and detailed insights into business segments [2] Group 1: Strategic Direction - CEO Klas Dahlberg will discuss the next phase of growth and value creation for HEXPOL [2] - The company aims to provide in-depth insights into market characteristics and future growth opportunities [1] Group 2: M&A Strategy - Magnus Berglund will present the company's M&A strategy, indicating a focus on expansion through acquisitions [2] Group 3: Business Segments - Presentations will cover various business segments, starting with the rubber compound section by Ralph Wolkener, Carsten Ruter, and Ken Bloom [2] - Following a break, Jan Wikström will discuss thermoplastic compounding and engineered products [2] - The final presentation will be delivered by Deputy CEO and CFO Peter Rosen, likely focusing on financial aspects [2]

Financial Data and Key Metrics Changes - Assertio reported total product sales of $49.5 million for Q3 2025, up from $28.7 million in the prior year, primarily driven by the Rosedown two-quarter pull forward [13] - Adjusted EBITDA for Q3 2025 was $20.9 million, significantly up from $4.4 million in the prior year, largely due to higher Rosedown sales [16] - GAAP net income for Q3 2025 was $11.4 million, compared to a loss of $3 million in the prior year [16] Business Line Data and Key Metrics Changes - Rosedown net product sales reached $38.6 million in Q3 2025, a substantial increase from $15 million in the same quarter last year, attributed to the pull forward of sales [7] - Synthesan net product sales grew to $2.8 million in Q3 2025, up from $2.6 million in the prior year, driven by higher volume [8][13] - Indocin sales decreased to $4.8 million in Q3 2025 from $5.7 million in the prior year, reflecting impacts from generic competition [14] Market Data and Key Metrics Changes - Rosedown achieved a 43% market share in the clinic Medicare Part B segment in Q3 2025, reflecting strong demand and strategic distribution efforts [10] - The company experienced a 42% year-to-date demand growth for Rosedown compared to the same period in 2024 [10] Company Strategy and Development Direction - The company aims to maintain price stability and predictability for Rosedown while pursuing further demand and market share growth [12] - Assertio is currently reviewing and refining its strategies moving forward under new leadership, focusing on growth assets [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's potential to generate significant value for patients and shareholders, highlighting a solid balance sheet and core growth assets [6] - The company anticipates a temporary decline in cash flow due to the Rosedown sales transition but expects improvement in Q2 2026 [16] Other Important Information - Assertio has executed a long-term supply agreement with its API manufacturer, ensuring stable supply and pricing for Rosedown [11] - The company is tightening its 2025 guidance, expecting full-year product sales between $110 million and $112 million and adjusted EBITDA between $14 million and $16 million [17] Q&A Session Summary Question: Linkage between labeler code and ASP for Rosedown - Management clarified that the labeler code change is not tied to ASP and emphasized a strategy of price stability and predictability [20] Question: Comments on Indocin market performance - Management noted good market share and volume for Indocin despite competition, with some price favorability observed [21] Question: Optimizing Rosedown's promotional and reimbursement strategy - Management is currently reviewing all strategies and will provide updates as refinements are made [24] Question: Expectations for Synthesan sales acceleration - Management indicated that Synthesan is competing in a generic market with a focus on raising awareness and promoting its unique delivery mechanism [30]

Product Performance - Assertio's lead product, ROLVEDON, was acquired on July 31, 2023, and is indicated to decrease the incidence of infection in adult patients receiving anti-cancer drugs [119]. - In the third quarter of 2025, ROLVEDON sales reflected both current demand and large purchases by national distributors, with expectations of no material net product sales in Q4 2025 and Q1 2026 [126]. - ROLVEDON net product sales increased by $23.5 million from $15.0 million in Q3 2024 to $38.6 million in Q3 2025, driven by higher volume despite lower net pricing [133]. - Total product sales, net for Q3 2025 reached $49.5 million, a significant increase from $28.7 million in Q3 2024, reflecting a year-over-year growth of approximately 72.5% [132]. - ROLVEDON net product sales increased by $23.2 million, from $44.6 million in 2024 to $67.8 million in 2025, driven by higher volume despite lower net pricing [153]. - Total product sales, net rose to $104.3 million in 2025, up from $91.3 million in 2024, marking an increase of approximately 14% [152]. Financial Performance - Total revenues increased to $105.2 million in 2025, compared to $92.8 million in 2024, reflecting a growth of approximately 13% [152]. - Loss from operations improved to $(9.8) million in 2025 from $(11.0) million in 2024, indicating a reduction in operational losses [152]. - The company recognized a loss of $8.2 million on the Assertio Therapeutics divestiture during the nine months ended September 30, 2025 [172]. - As of September 30, 2025, the company reported cash and cash equivalents totaling $93.4 million, expected to fund operations and debt payments for the next 12 months [177]. - Net cash provided by operating activities decreased to $1.8 million for the nine months ended September 30, 2025, down from $14.9 million in the same period of 2024, primarily due to lower cash generated from operating assets and liabilities [183]. - Cash flows from operating activities are expected to decline in the fourth quarter of 2025 and first quarter of 2026, before increasing in the second quarter of 2026 due to the timing of cash collections [186]. Expenses and Costs - Cost of sales rose by $6.1 million from $7.6 million in Q3 2024 to $13.7 million in Q3 2025, primarily due to increased ROLVEDON volumes [139]. - Research and development expenses decreased from $1.0 million in Q3 2024 to $0.4 million in Q3 2025, reflecting reduced costs associated with ongoing clinical trials [141]. - Selling, general and administrative expenses slightly increased by $0.2 million from $16.7 million in Q3 2024 to $16.9 million in Q3 2025, influenced by one-time costs related to ceasing commercialization of Otrexup [143]. - Amortization of intangible assets decreased from $6.7 million in Q3 2024 to $5.6 million in Q3 2025, primarily due to the full amortization of INDOCIN intangible assets [147]. - Research and development expenses decreased from $2.5 million in 2024 to $1.2 million in 2025, a reduction of 52% [159]. - Selling, general and administrative expenses increased by $2.2 million, from $53.6 million in 2024 to $55.9 million in 2025, primarily due to legal charges and one-time costs [160]. - Amortization of intangible assets increased by $5.1 million, from $19.0 million in 2024 to $24.1 million in 2025, primarily due to changes in estimated useful life of ROLVEDON product rights [163]. Strategic Initiatives - Assertio anticipates reduced cash collections and a decline in cash and short-term investments for Q4 2025 and Q1 2026 due to extended payment terms provided to customers [127]. - Assertio's commercial capabilities include a patient-centric approach and an omni-channel promotional model, enhancing accessibility to a broader patient population [122]. - The company is working to identify further opportunities for ROLVEDON, including potential inclusion in National Comprehensive Cancer Network guidelines [119]. - Assertio's integration efforts aim to consolidate operations and align products under a single subsidiary, Assertio Specialty [126]. - The company has fixed the price for the remaining term of its license agreement with Hanmi Pharmaceutical Co. Ltd. through an amendment to the Manufacturing and Supply Agreement [129]. - Assertio's executive leadership team possesses extensive commercial execution and business development experience, supporting its commercial capabilities [122]. Legal and Compliance - Assertio Therapeutics was divested on May 9, 2025, resulting in no opioid-related litigation against the company [123][124]. - The company recorded a full valuation allowance against its net deferred tax asset as of September 30, 2025, indicating uncertainty regarding realization [174]. - The company anticipates ongoing legal expenses and potential settlements will continue to significantly impact cash usage through the remainder of 2025 [179]. - The company was in compliance with covenants related to the 2027 Convertible Notes as of September 30, 2025 [181]. Cash Flow and Financing - Cash used in investing activities for the nine months ended September 30, 2025, was $13.7 million, compared to $50.0 million in the same period of 2024, reflecting a significant reduction in investment outflows [187][188]. - The company experienced a net cash use of $20.5 million from operating assets and liabilities for the nine months ended September 30, 2025, compared to $2.1 million in the same period of 2024, largely due to increased accounts receivable from ROLVEDON inventory sales [185]. - The company issued $70.0 million in convertible senior notes on August 22, 2022, with a maturity date of September 1, 2027, and an interest rate of 6.5% per annum [180]. - Cash used in financing activities was $0.2 million for the nine months ended September 30, 2025, consistent with $0.3 million in the same period of 2024, primarily for employee stock award tax liabilities [189]. - The company may need to raise additional capital if cash needs vary significantly from current expectations, which could adversely affect its operations [179].

Financial Performance - Assertio reported third quarter 2025 net product sales of $49.5 million, up from $28.7 million in the prior-year quarter, representing a 72% increase[9]. - Rolvedon net product sales reached $38.6 million for Q3 2025, significantly up from $15.0 million in the same quarter last year, reflecting a 157% increase[6]. - Total revenues for Q3 2025 reached $49,459,000, a 69% increase from $28,705,000 in Q3 2024[20]. - Product sales contributed $49,459,000 to total revenues, compared to $28,705,000 in the same quarter last year, indicating a significant growth[20]. - Net income for Q3 2025 was $11,445,000, compared to a net loss of $2,921,000 in Q3 2024[20]. - Basic net income per share for Q3 2025 was $0.12, while diluted net income per share was $0.11[20]. - Adjusted EBITDA for Q3 2025 was $20.9 million, compared to $4.4 million in the prior-year quarter, marking a 373% increase[9]. - Adjusted earnings (Non-GAAP) for the three months ended September 30, 2025, were $18.987 million, or $0.18 per share, compared to $1.764 million, or $0.02 per share, for the same period in 2024[30]. Sales and Revenue Guidance - Assertio narrowed its FY2025 net product sales guidance to a range of $110 million to $112 million, and adjusted EBITDA guidance to $14 million to $16 million[3]. Expenses and Costs - SG&A expenses were $16.9 million for Q3 2025, slightly up from $16.7 million in the prior-year quarter, reflecting non-recurring costs related to the decommercialization of Otrexup[6]. - Research and development expenses for the nine months ended September 30, 2025, were $1,204,000, down from $2,536,000 in the same period last year[20]. - The company reported restructuring costs of $289,000 for the nine months ended September 30, 2025, compared to $720,000 for the same period in 2024[33]. - The company reported stock-based compensation expenses of $3.357 million for the nine months ended September 30, 2025, compared to $3.911 million for the same period in 2024[33]. - The company incurred $5.060 million in expenses related to the decommercialization of Otrexup for the nine months ended September 30, 2025[33]. Assets and Liabilities - Cash, cash equivalents, and short-term investments totaled $93.4 million as of September 30, 2025, down from $98.2 million as of June 30, 2025[6]. - Total current assets increased to $263,573,000 as of September 30, 2025, up from $202,549,000 at the end of 2024[22]. - Cash and cash equivalents decreased to $38,500,000 from $50,588,000 at the end of 2024[22]. - Total liabilities rose to $213,972,000 as of September 30, 2025, compared to $163,651,000 at the end of 2024[22]. Management and Strategic Focus - Paul Schwichtenberg was promoted to President and COO, indicating a strategic focus on enhancing commercial strategies for future growth[8]. Other Financial Metrics - Adjusted EBITDA for the nine months ended September 30, 2025, was $26,815,000, compared to $14,852,000 in the same period of 2024[25]. - The company reported a net cash provided by operating activities of $1,786,000 for the nine months ended September 30, 2025, down from $14,860,000 in the prior year[24]. - For the nine months ended September 30, 2025, the company experienced a net loss of $18.448 million, with a diluted EPS of $(0.19), compared to a net loss of $11.105 million and a diluted EPS of $(0.12) for the same period in 2024[33]. - Legal settlements, net of insurance proceeds, contributed $3.543 million to adjusted earnings for the nine months ended September 30, 2025, compared to a negative impact of $2.816 million in 2024[33]. - Amortization of intangible assets for the nine months ended September 30, 2025, was $24.059 million, up from $18.973 million in the same period in 2024[33]. - The company recognized a loss of $8.2 million from the divestiture of the Assertio Therapeutics subsidiary, which included approximately $1.0 million in one-time costs[28].